Day: June 25, 2021

BRIDGEWATER, N.J., June 25, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced the pricing of an underwritten public offering of 38,461,538 shares of its common stock at a public offering price of $2.60 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Synchronoss, are expected to be $100 million. In addition, Synchronoss has granted the underwriters a 30-day option to purchase up to 3,846,154 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.

All of the shares in the offering are being sold by Synchronoss. Synchronoss anticipates using the net proceeds from the offering, and from the offering of Senior Notes and sale of Series B Preferred Stock (each as described below), to fully redeem all outstanding shares of Synchronoss’ Series A Convertible Participating Perpetual Preferred Stock and repay amounts outstanding under Synchronoss’ revolving credit facility. The offering is expected to close on or about June 29, 2021, subject to satisfaction of customary closing conditions.

B. Riley Securities, Inc. (“BRS”) is acting as the lead underwriter and sole book-running manager for the offering. Northland Capital Markets is acting as co-manager for the offering.

Concurrently with the offering, the Company is offering, by means of a separate prospectus supplement, $120 million aggregate principal amount of senior notes due 2026 (the “Senior Notes”). In addition, B. Riley Principal Investments, LLC (“BRPI”), an affiliate of BRS, has entered into an agreement pursuant to which BRPI has agreed to purchase $75.0 million of the Company’s Series B Preferred Stock in a private transaction to be completed concurrently with the closing of the offering.

The shares of common stock described above are being offered by Synchronoss pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on August 28, 2020. A preliminary prospectus supplement relating to and describing the terms of the offering is filed with the SEC and is available on the SEC’s web site at www.sec.gov. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. Copies of the final prospectus supplement (when available) and accompanying prospectus relating to these securities may also be obtained by sending a request to: B. Riley Securities, Inc., at 1300 North 17th Street, Suite 1300, Arlington, VA 22209 or by calling (703) 312‐9580 or by emailing prospectuses@brileyfin.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the closing of the public offering and the anticipated use of the proceeds thereof. These forward-looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the public offering and the risk factors set forth from time to time in Synchronoss’ SEC filings, including but not limited to the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections (as applicable) of Synchronoss’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the period ended March 31, 2021, which are on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Synchronoss’ other filings with the SEC, other unknown or unpredictable factors also could affect Synchronoss’ results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Synchronoss undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media

Diane Rose
CCgroup
synchronoss@ccgrouppr.com

Investors

Todd Kehrli/Joo-Hun Kim
MKR Investor Relations, Inc.
investor@synchronoss.com

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Launch of Proposed Public Offering in the United States

Mont-Saint-Guibert, Belgium – June 25, 2021, 12:30 pm CET / 6:30 am ET – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it is launching an underwritten registered public offering of 2,760,000 ordinary shares in the United States (the “Offering”) at an assumed public offering price of $31.46¹.

In connection with the Offering, Nyxoah intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares offered in the Offering on the same terms and conditions.

The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the size or terms of the Offering, including the price per ordinary share (in USD) and number of ordinary shares sold in the Offering.

Nyxoah’s ordinary shares are currently listed on Euronext Brussels under the symbol “NYXH”. An application has been made to list the ordinary shares on the NASDAQ Global Market under the same symbol.

Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the Offering. Degroof Petercam is acting as a co-manager.

A registration statement on Form F-1 has been filed with the SEC but has not yet become effective. The ordinary shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The Offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the terms of the Offering. Forward-looking statements are based on Nyxoah’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward-looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated. A prospectus will be prepared by Nyxoah in accordance with Article 3 of the Prospectus Regulation for the purpose of having the new shares that will be represented by ordinary shares admitted to trading on Euronext Brussels. In the context of the Offering and in accordance with Belgian law and the articles of association of Nyxoah, the board of directors of Nyxoah has approved a conditional capital increase with issuance of up to 4,600,000 ordinary shares within the framework of the authorized capital granted to the board of directors as set out in article 7 of the articles of association of Nyxoah.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

---

¹ Equivalent to a public offering price of €26.50 per ordinary share, assuming an exchange rate of  €1.00 = $1.1872, the noon buying rate in The City of New York on June 18, 2021 set forth in the H.10 statistical release of the Federal Reserve Board on June 21, 2021.

Attachment

• Nyxoah – US IPO – Launch PR (ENG)

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease  
 
JUNE 25, 2021 – ORPHAN DISEASES 

— CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy for patients with Wilson’s Disease, following six months of treatment.

— Trientine tetrahydrochloride was well tolerated and during treatment, more patients achieved the pre-specified composite endpoint of NCC and 24–hour Urinary Copper Excretion (UCE) within therapeutic target ranges, compared to patients treated with d-Penicillamine, 50% versus 24%.  

— Data from the trial to be presented today during an oral presentation at EASL’s The International Liver Congress™ 2021. 

Paris, France. June 25, 2021 (GLOBE NEWSWIRE) Orphalan SA is a company that identifies, develops and delivers innovative treatments to patients with rare diseases. Orphalan today announced positive top line results from a phase 3 head-to-head trial comparing d-Penicillamine with trientine tetrahydrochloride in Wilson’s Disease (WD). The phase 3 trial has been completed through an IND program for FDA submission. Wilson’s Disease is a rare inherited disorder of copper transport primarily affecting the liver and brain. Untreated, this is a fatal disease.

The CHELATE trial is the first prospective randomised trial comparing d-Penicillamine with trientine tetrahydrochloride. D- Penicillamine has been the only approved first line treatment for the last 70 years. Trientine tetrahydrochloride if approved has the potential to be used as maintenance therapy in patients with Wilson’s Disease.

The CHELATE trial met its primary efficacy endpoint by demonstrating that trientine tetrahydrochloride was non-inferior to d-Penicillamine as measured by copper speciation evaluation of non-ceruloplasmin copper (NCC). This novel analytical method was developed by Orphalan through consultation with the FDA. The pre-specified composite endpoint of non-ceruloplasmin copper (NCC) and 24-hour urinary copper excretion (UCE), was achieved by 50% of patients treated with trientine tetrahydrochloride versus 24% of patients treated with d-Penicillamine.

Five serious adverse events (SAEs) were observed in the 27 patients treated with d-Penicillamine, while no SAEs were observed in the 26 patients randomised to trientine tetrahydrochloride. Treatment emergent adverse events (TEAEs) temporally related to the study treatments reported in the study were comparable in both groups and were graded as either mild or moderate and transitory in nature.

The data arising from this study will be presented at EASL’s International Liver Congress today at 8.45 CEST and will be submitted for publication. Analysis of the 48-week data from the CHELATE Phase 3 investigational study is ongoing and will be presented at a future scientific forum.

“With a chronic disorder like Wilson’s Disease, interrupting or stopping treatment for any reason can provoke the return of disease activity, sometimes with severe consequences. Physicians and patients should work together to choose a medication that provides the right balance of efficacy, safety and tolerability to help manage patients’ Wilson’s Disease and meet their treatment goals,” said Dr. Michael Schilsky , Principal Investigator and Professor of Medicine and Director of the Center for Excellence for Wilson Disease at Yale University. “These top-line results suggest that trientine tetrahydrochloride offers a differentiated tolerability profile and represents a safe and effective alternative to d-Penicillamine as a maintenance therapy for patients with Wilson’s Disease.”

“Despite its poor safety profile, d-Penicillamine is the only approved first line therapy in Wilson’s Disease. The CHELATE study showed that patients on d-Penicillamine can be safely switched to trientine tetrahydrochloride, without compromising efficacy. Our commitment to this study is in line with our strategy to provide robust clinical data to physicians to enable them to make evidence-based treatment decisions.” said Dr. Naseem Amin, Chief Executive Officer at Orphalan. He added: “The clinical evidence from this trial and the use of the novel assay for NCC developed by Orphalan have the potential to make a meaningful difference to the patient’s life and the physician’s ability to monitor their disease.”

Notes to Editors

About the CHELATE Study

CHELATE is a Phase 3, multicentre, randomised, open label, active-controlled, non-inferiority study conducted in 9 countries at 15 centres designed to evaluate efficacy and safety of trientine tetrahydrochloride compared to d-Penicillamine in patients with stable Wilson’s Disease. Fifty-three adult Wilson’s Disease patients with clinically stable disease for over one year and who met specific inclusion criteria, including laboratory measures of serum non-ceruloplasmin copper (NCC), 24-hour urinary copper excretion (UCE) and liver function tests, were followed for a baseline period for 12 weeks before being randomised 1:1 to either trientine tetrahydrochloride or d-Penicillamine twice daily. The study’s primary endpoint was serum NCC as measured using Orphalan’s proprietary method using copper speciation at 24-weeks post-randomisation. A secondary composite efficacy endpoint was NCC and 24-hour UCE.

Additional secondary endpoints included were: clinical Global Impression of Change (CGIC) score; serum copper and ceruloplasmin levels; the unified Wilson’s Disease Rating Scale (UWDRS); modified Nazer score; cognitive assessments and standard safety assessments. In addition, an independent adjudication committee blinded to the allocated treatment, and study centres assessed key efficacy and safety parameters to determine clinical stability of the patient. 

About Trientine Tetrahydrochloride
Trientine tetrahydrochloride is an investigational, novel oral trientine formulation with Orphan Drug Designation under development through a 505(b)(2) pathway for the treatment of Wilson’s Disease maintenance patients. The trientine tetrahydrochloride NDA is planned to be submitted mid-year 2021. If approved by the FDA, Orphalan intends to market trientine tetrahydrochloride itself in the US.

About the Trientine Tetrahydrochloride Clinical Development Program
The key components of the clinical development program of trientine tetrahydrochloride include the CHELATE trial, a Phase 3, open-label, six-month safety and efficacy study in maintenance Wilson’s Disease patients, along with pharmacokinetic bridging studies comparing trientine tetrahydrochloride to two formulations of trientine dihydrochloride, Triumph I and Triumph 2. The CHELATE clinical development program also includes the CHELATE extension phase, assessing the safety, efficacy and tolerability of trientine tetrahydrochloride and d-Penicillamine over a period of 1 year. 

About Cuprior™
Cuprior™ is a form of trientine tetrahydrochloride which is approved in the EU for patients intolerant to d-Penicillamine. Of the estimated 5,000 diagnosed Wilson’s Disease patients in the EU, we estimate 25% are considered intolerant.

Cuprior™ is contraindicated in patients hypersensitive to trientine.

Cuprior™ is a registered and unregistered trademark of Orphalan.

For important safety information and full prescribing information, including patient information for Cuprior™ please visit  https://www.cuprior.com

Trientine tetrahydrochloride is under investigation and not approved for use in any indication in the United States.

About Orphalan
At Orphalan, our mission is clear: we are pioneers in orphan diseases. Orphalan is a company that identifies, develops and delivers innovative treatments to patients with rare diseases. Orphalan was founded in 2011 and has launched Cuprior™ across Europe with its own commercial organisation.

Contact for Orphalan:
Tel : +33 (0)1 42 49 82 64
info@orphalan.health

Contact For Media:
Consilium Strategic Communications: 
Mary-Jane Elliott, Allison Connolly
Tel: +44 (0) 203 709 5700
orphalan@consilium-comms.com

TORONTO, June 24, 2021 (GLOBE NEWSWIRE) — The Association of the Families of Flight PS752 Victims (the Association) welcomes the Government of Canada’s Forensic Examination and Assessment report on the downing of Ukraine International Airlines flight PS752, released today. That report exposes the Iranian regime’s disregard for human life, failure to disclose the truth and pursue justice, and oppression of victims’ families. The Association welcomes Canada’s commitment in the report to pursuing the truth and justice, including to the International Court of Justice, and calls for the international community to hold the Islamic Republic fully accountable for what it believes to be the willful murder of their loved ones.

The Iranian regime had an obligation to transparently disclose the causes of the downing of Flight PS752 through a comprehensive report in cooperation with the affected countries. Iran had failed to meet that obligation.

Canada’s decision to conduct its own forensic examination and assessment was an important step. But it is not sufficient and cannot be the final summary of what transpired on January 8, 2020. The Report makes clear that the investigators lacked access to witnesses, fulsome evidence and sufficient information. The Government of Canada must continue its work to hold the culprits of this crime to account and bring justice to the victims, their families, and their loved ones. Even without access to much important information, the forensic examination report reveals Iran’s failure to investigate its shooting of Flight PS752 and its failure to comply with international law.

Prime Minister Justin Trudeau’s own conclusions outlined in the report speak to the intentional obfuscation and lack of accountability, cooperation and transparency on the part of the Iranian regime, and the need to hold Iran to account at the highest levels:

“Iran’s official account of events is disingenuous, misleading and superficial and intentionally ignores key factors.”

“Iran must also account for the cover-up that followed the downing of flight PS752, including bulldozing the crash site before investigators arrived.”

“… Should negotiations with Iran not result in an acceptable outcome for Canada on behalf of the families, we will pursue all available options, including recourse to the International Court of Justice.”

Canada’s forensic report makes several key observations that clearly illustrate the crimes, obfuscations and lies of Iran. First, the report rejects the Islamic Regime’s claims of “human error” as not plausible, and finds senior officials of Iran culpable. The report finds that it is not plausible that the crime was committed by a low-level operator in the field who failed to perform his duties and misjudged the situation, without regular communications with central military commanders. The report highlights the likely involvement of higher-level military and other government officials in shooting Flight PS752. The report states that although the firing of the missiles may have been delegated to a lower ranking operator, “… it is very unlikely the SAM operator would have been authorized to launch missiles without approval from his command.”

The forensic report further emphasizes that there was “… no evidence that ‘jamming’ or electronic warfare were the cause”, contrary to statements made by Iran that the missile operators had lost contact with central commanders. UN Special Rapporteur on Extrajudicial, Summary or Arbitrary Executions, Agnes Callamard, stated that: “The inconsistencies in the official explanations seem designed to create a maximum of confusion and a minimum of clarity. They seem contrived to mislead and bewilder.”

Importantly, the forensic report finds that the foundation of this crime lies with high-level strategic and national security decisions of Iran, likely made by the leader of the Islamic regime and the Supreme Council of National Security of Iran. They deliberately kept the civilian airspace open at a time of heightened military tension, and after launching an attack, possibly using PS752 passengers and other passengers on aircraft that departed earlier that morning as human shields. There are still numerous unanswered questions and facts suggesting that the downing of the civilian airliner PS752 was intentional. The onus is on Iran to transparently disclose all relevant information in order to show that the downing of PS752 was not intentional.

The revelations of Canada’s Forensic Report underscore what the Association and families have long known and further energize the families’ resolve in their fight for truth and justice. The Association’s Fact-Finding Committee intends to produce a report of its own findings and conclusions in the coming months and the Association will continue to seek an international platform that will hold the Iranian regime to account for their actions. The Association of the Families of Flight PS752 Victims requests that the Government of Canada to put forth a substantial monetary reward for any information that leads to identification and prosecution of those individuals responsible for the shooting of Flight PS752. The Association once more insists that the Government of Canada enlist the IRGC as a terrorist entity, impose targeted Magnitsky sanctions on the perpetrators of the downing, and pursue the PS752 file through a domestic criminal investigation.

For more information, contact

Colleen Ryan
Cell: 647-232-6867
Email: cryan@sussex-strategy.com

Hamed Esmaeilion
Email: speaker@ps752justice.com
Website: https://www.ps752justice.com

BRIDGEWATER, N.J., June 24, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that the Company intends to offer and sell, subject to market and other conditions, $120 million aggregate principal amount of senior notes due 2026 in an underwritten public offering. Synchronoss also expects to grant the underwriters a 30-day option to purchase an additional $5 million aggregate principal amount of senior notes in connection with the offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Synchronoss and the senior notes both received a rating of BB- from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.

All of the senior notes in the offering are to be sold by Synchronoss, with net proceeds of the offering, and of the anticipated offering of common stock and sale of Series B Preferred Stock (each as described below), expected to be used to fully redeem all outstanding shares of Synchronoss’ Series A Convertible Participating Perpetual Preferred Stock and repay amounts outstanding under Synchronoss’ revolving credit facility.

B. Riley Securities, Inc. (“BRS”) is acting as the sole book-running manager for the offering. Northland Capital Markets, Aegis Capital Corp. and EF Hutton, division of Benchmark Investments, LLC are acting as lead managers for the offering.

Concurrently with the offering, the Company anticipates offering, by means of a separate prospectus supplement, $100 million of shares of its common stock. In addition, B. Riley Principal Investments, LLC (“BRPI”), an affiliate of BRS, has entered into an agreement pursuant to which BRPI has agreed to purchase $75.0 million of the Company’s Series B Preferred Stock in a private transaction to be completed concurrently with the closing of the offering.

The senior notes described above are being offered by Synchronoss pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on August 28, 2020. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained by sending a request to: B. Riley Securities, Inc., at 1300 North 17th Street, Suite 1300, Arlington, VA 22209 or by calling (703) 312‐9580 or by emailing prospectuses@brileyfin.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the public offering and the anticipated use of the proceeds thereof. These forward-looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the proposed public offering and the risk factors set forth from time to time in Synchronoss’ SEC filings, including but not limited to the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections (as applicable) of Synchronoss’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the period ended March 31, 2021, which are on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Synchronoss’ other filings with the SEC, other unknown or unpredictable factors also could affect Synchronoss’ results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Synchronoss undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media

Diane Rose
CCgroup
diane@ccgrouppr.com

Investors

Todd Kehrli/Joo-Hun Kim
MKR Investor Relations, Inc.
investor@synchronoss.com

ผู้ชนะรางวัล SmartEdge Partner Program ได้แก่ Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India และ Enthu Technology Sdn Bhd

เออร์ไวน์, แคลิฟอร์เนีย, June 25, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX) ผู้ให้บริการโซลูชันแบบครบวงจรที่ปลอดภัยสำหรับ Internet of Things (IoT) และ Remote Environment Management (REM) ที่นำเสนอ Software as a Service (SaaS), บริการเชื่อมต่อ, บริการวิศวกรรม และฮาร์ดแวร์อัจฉริยะ วันนี้ได้ประกาศผู้ชนะรางวัล SmartEdge™ Partner Program Awards โดยมีการมอบรางวัลในการประชุม SmartEdge Partner Summit 2021 ของ Lantronix ที่จัดขึ้นแบบเสมือนจริงในวันที่ 23 มิถุนายน 2021

รางวัล SmartEdge Partner Program Awards ของ Lantronix นั้นแบ่งออกเป็น 3 ประเภท: Distribution Partner, StrategicEdge Partner และ Edge Partner ใน 3 ภูมิภาค ได้แก่: อเมริกาเหนือ, ยุโรป/ตะวันออกกลาง/แอฟริกาและเอเชียแปซิฟิก

โดยมีผู้ชนะรางวัลดังต่อไปนี้:
อเมริกาเหนือ
North America Distributor Partner of the Year: Tech Data
North America StrategicEdge Partner of the Year: SHI
North America Edge Partner of the Year: Presidio

ยุโรป/ตะวันออกกลาง/แอฟริกา (EMEA)
EMEA Distributor Partner of the Year: Atlantik Elektronik
EMEA StrategicEdge Partner of the Year: Arki Technology
EMEA Edge Partner of the Year: Data Equipment

เอเชียแปซิฟิก (APAC)
APAC Distributor Partner of the Year: Acromax
APAC StrategicEdge Partner of the Year: Rahi Systems, India
APAC Edge Partner of the Year: Enthu Technology Sdn. Bhd

“เรายินดีที่จะมอบรางวัลแก่ผู้ชนะ SmartEdge Partner Program ซึ่งทั้งหมดต่างทำได้ดีกว่าความต้องการและความคาดหวังของโปรแกรมในการขับเคลื่อนการขายและการสร้างความสัมพันธ์ระยะยาวกับลูกค้าที่เรามีร่วมกัน” Roger Holliday รองประธานฝ่ายขาย WW ที่ Lantronix กล่าว

วันครบรอบ 1 ปี SmartEdge Partner Program

Lantronix ฉลองการครบรอบ 1 ปีของ SmartEdge Partner Program ใหม่ในเดือนเมษายน 2021 “SmartEdge Partner Program ของ Lantronix ได้ดึงดูดพันธมิตรช่องทางชั้นนำของอุตสาหกรรม” Jonathan Shipman รองประธานฝ่ายกลยุทธ์ที่ Lantronix กล่าว “SmartEdge Program ของเราจะช่วยให้พันธมิตรช่องทางของเราสามารถนำเสนอข้อเสนอซอฟต์แวร์ ฮาร์ดแวร์และโซลูชันบริการแบบผสานรวมของ Lantronix มอบทุกสิ่งที่ลูกค้าต้องการในการสร้างโซลูชันที่อิงกับการเชื่อมต่อที่ปลอดภัยและมีประสิทธิภาพ”

Lantronix ได้รับการกล่าวถึงใน CRN Partner Program Guide

SmartEdge Partner Program ของ Lantronix ได้รับการกล่าวถึงในนิตยสารโปรแกรมพันธมิตรชั้นนำของอุตสาหกรรม CRN Partner Program Guide ที่เผยแพร่โดย CRN^® ซึ่งเป็นแบรนด์หนึ่งของ The Channel Company โดยให้ข้อมูลสรุปเกี่ยวกับโปรแกรมพันธมิตรที่โดดเด่นที่สุดจากบริษัทเทคโนโลยีชั้นนำที่ให้บริการผลิตภัณฑ์และบริการผ่านช่องทางไอที ดู 2021 Partner Program Guide แบบออนไลน์ได้ที่ www.CRN.com/PPG

เกี่ยวกับ SmartEdge Partner Program

SmartEdge™ Partner Program ของ Lantronix ถูกออกแบบมาเพื่อช่วยให้ Value-Added Reseller (VAR) และ Systems Integrator (SI) ขับเคลื่อนรายได้ด้วยการสร้างความแตกต่างให้ข้อเสนอด้วยโซลูชัน Industrial Internet of Things (IoT), Remote Environment Management (REM), Out-of-Band Management (OOBM) และ Mobility/Connectivity อันล้ำสมัยของ Lantronix
สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Lantronix SmartEdge Partner Program โปรดไปที่ www.lantronix.com/partners

เกี่ยวกับ Lantronix

Lantronix Inc. ผู้ให้บริการโซลูชันแบบครบวงจรที่ปลอดภัยสำหรับ Internet of Things (IoT) และ Remote Environment Management (REM) ที่นำเสนอ Software as a Service (SaaS), บริการเชื่อมต่อ, บริการวิศวกรรม และฮาร์ดแวร์อัจฉริยะ Lantronix ช่วยให้ลูกค้าสามารถจัดหาโซลูชันที่เชื่อถือได้และปลอดภัยพร้อมกับเร่งเวลาในการนำออกสู่ตลาด ผลิตภัณฑ์และบริการของ Lantronix ทำให้การดำเนินงานง่ายขึ้นอย่างมากผ่านการสร้างสรรค์ การพัฒนา การปรับใช้และการจัดการโครงการของลูกค้าตามขนาดพร้อมกับมอบคุณภาพ ความน่าเชื่อถือและความปลอดภัย

ด้วยประสบการณ์ที่ผ่านการพิสูจน์มาแล้วสามทศวรรษในการสร้างเทคโนโลยี IoT และโซลูชัน OOBM ที่แข็งแกร่ง Lantronix เป็นผู้คิดค้นนวัตกรรมที่จะช่วยให้ลูกค้าของเราสามารถสร้างโมเดลธุรกิจใหม่ ใช้ประโยชน์จากประสิทธิภาพที่เพิ่มขึ้นและสามารถรับรู้ถึงความเป็นไปได้ของ Internet of Things ได้ โซลูชันของ Lantronix มีการใช้งานภายในเครื่องจักรนับล้านเครื่องที่ศูนย์ข้อมูล สำนักงาน และไซต์งานระยะไกล ซึ่งให้บริการในอุตสาหกรรมต่างๆ มากมาย รวมถึงด้านพลังงาน เกษตรกรรม การแพทย์ การรักษาความปลอดภัย การผลิต การจัดจำหน่าย การขนส่ง การค้าปลีก การเงิน สิ่งแวดล้อม และรัฐบาล

Lantronix มีสำนักงานใหญ่อยู่ในเมืองเออร์ไวน์ รัฐแคลิฟอร์เนีย สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.lantronix.com เรียนรู้เพิ่มเติมที่บล็อก Lantronix www.lantronix.com/blog ที่มีการอภิปรายและการอัปเดตด้านอุตสาหกรรม สำหรับการติดตาม Lantronix บน Twitter โปรดไปที่ www.twitter.com/Lantronix ดูไลบรารีวิดีโอของเราบน YouTube ได้ที่ www.youtube.com/user/LantronixInc หรือติดต่อกับเราบน LinkedIn ได้ที่ www.linkedin.com/company/lantronix

แถลงการณ์ “หลักอ่าวที่ปลอดภัย” (Safe Harbor) ภายใต้กฎหมายปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี 1995: แถลงการณ์ใดๆ ที่ระบุไว้ในข่าวประชาสัมพันธ์ฉบับนี้ ซึ่งไม่ใช่เนื้อหาทางประวัติศาสตร์และข้อเท็จจริงทั้งหมด รวมถึงแต่ไม่จำกัดเฉพาะข้อความที่เกี่ยวข้องกับโซลูชัน เทคโนโลยีและผลิตภัณฑ์ของเรา เป็นข้อความเชิงคาดการณ์เหตุการณ์ในอนาคต ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตนี้อ้างอิงจากการคาดการณ์ในปัจจุบันของเราและอาจอยู่ภายใต้ความเสี่ยงและความไม่แน่นอนที่อาจก่อให้เกิดผลประกอบการที่แท้จริงของเรา ธุรกิจในอนาคต สถานะทางการเงินหรือผลการดำเนินงานที่แตกต่างอย่างมากจากผลประกอบการในอดีตของเรา คำสั่งที่มีอยู่ในข่าวประชาสัมพันธ์นี้หรือที่กล่าวโดยชัดแจ้งหรือโดยนัยในข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตใดๆ ที่ปรากฏอยู่ในข่าวเผยแพร่นี้ ความเสี่ยงและความไม่แน่นอนที่อาจเกิดขึ้นได้ รวมถึงแต่ไม่จำกัดเพียงปัจจัยต่างๆ เช่น ผลกระทบจากสภาวะทางเศรษฐกิจในภูมิภาคและทั่วโลกที่ส่งผลกระทบในทางลบหรือแย่ลงหรือส่งผลกระทบต่อความไม่แน่นอนในตลาดในธุรกิจของเรา รวมถึงผลกระทบต่อการตัดสินใจซื้อของลูกค้าของเรา ผลกระทบของการแพร่ระบาดของโควิด-19 ต่อพนักงานของเรา ห่วงโซ่อุปทานและห่วงโซ่การกระจายสินค้า และเศรษฐกิจโลก ความเสี่ยงด้านการรักษาความปลอดภัยทางไซเบอร์ การเปลี่ยนแปลงกฎหมาย กฎระเบียบ และภาษีของรัฐบาลสหรัฐอเมริกาและกฎหมายต่างประเทศที่บังคับใช้ ความสามารถของเราในการใช้กลยุทธ์การเข้าซื้อกิจการของเราสำเร็จหรือรวม บริษัทที่ได้มา ความยุ่งยากและค่าใช้จ่ายในการคุ้มครองสิทธิบัตรและสิทธิในทรัพย์สินอื่นๆ ระดับของหนี้สินของเราความสามารถของเราในการให้บริการหนี้ของเราและข้อจำกัดในสัญญาหนี้ของเรา และปัจจัยเพิ่มเติมใดๆ ที่รวมอยู่ในรายงานประจำปีของเราในแบบฟอร์ม 10-K สำหรับปีงบการเงินสิ้นสุดวันที่ 30 มิถุนายน 2020 ซึ่งยื่นต่อสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ (“SEC”) เมื่อวันที่ 11 กันยายน 2020 รวมถึงในหัวข้อ “ปัจจัยเสี่ยง” ในข้อ 1A ของส่วนที่ 1 ของรายงานดังกล่าวรวมถึงในเอกสารที่เรายื่นต่อสาธารณะอื่นๆ กับ SEC อาจมีการระบุปัจจัยเสี่ยงเพิ่มเติมเป็นครั้งคราวในเอกสารที่เรายื่นในอนาคต ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่รวมอยู่ในข่าวประชาสัมพันธ์ฉบับนี้จะกล่าวถึง ณ วันที่ในที่นี้ และเราไม่มีข้อผูกมัดใดๆ ในการปรับปรุงข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้เพื่อสะท้อนเหตุการณ์หรือสถานการณ์ที่ตามมา

© 2021 Lantronix, Inc. สงวนลิขสิทธิ์ Lantronix เป็นเครื่องหมายการค้าจดทะเบียนและ EMG และ ConsoleFlow เป็นเครื่องหมายการค้าของ Lantronix Inc. เครื่องหมายการค้าและชื่อทางการค้าอื่นๆ เป็นเครื่องหมายการค้าของเจ้าของที่เกี่ยวข้อง

© 2021 CRN เป็นเครื่องหมายการค้าจดทะเบียนของ The Channel Company, LLC สงวนลิขสิทธิ์

ติดต่อด้านสื่อ Lantronix:
Gail Kathryn Miller
ผู้จัดการแผนกการตลาดองค์กร และ
การสื่อสาร
media@lantronix.com
949-453-7158

ติดต่อนักวิเคราะห์และนักลงทุน Lantronix:
Jeremy Whitaker
ประธานเจ้าหน้าที่ฝ่ายการเงิน
investors@lantronix.com
949-450-7241

ฝ่ายขายของ Lantronix:
sales@lantronix.com
อเมริกา +1 (800) 422-7055 (สหรัฐอเมริกาและแคนาดา) หรือ +1 949-453-3990
ยุโรป ตะวันออกกลาง และแอฟริกา +31 (0)76 52 36 744
เอเชียแปซิฟิก + 852 3428-2338
จีน + 86 21-6237-8868
ญี่ปุ่น +81 (0) 50-1354-6201
อินเดีย +91 994-551-2488

BRIDGEWATER, N.J., June 24, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that the Company intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. Synchronoss also expects to grant the underwriters a 30-day option to purchase up to an additional $10 million of shares of common stock sold in the offering, at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

All of the shares in the offering are to be sold by Synchronoss, with net proceeds of the offering, and from the offering of Senior Notes and sale of Series B Preferred Stock (each as described below), expected to be used to fully redeem all outstanding shares of Synchronoss’ Series A Convertible Participating Perpetual Preferred Stock and repay amounts outstanding under Synchronoss’ revolving credit facility.

B. Riley Securities, Inc. (“BRS”) is acting as the lead underwriter and sole book-running manager for the offering. Northland Capital Markets is acting as co-manager for the offering.

Concurrently with the offering, the Company is offering, by means of a separate prospectus supplement, $120 million aggregate principal amount of senior notes due 2026 (the “Senior Notes”). In addition, B. Riley Principal Investments, LLC (“BRPI”), an affiliate of BRS, has entered into an agreement pursuant to which BRPI has agreed to purchase $75.0 million of the Company’s Series B Preferred Stock in a private transaction to be completed concurrently with the closing of the offering.

The shares of common stock described above are being offered by Synchronoss pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on August 28, 2020. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained by sending a request to: B. Riley Securities, Inc., at 1300 North 17th Street, Suite 1300, Arlington, VA 22209 or by calling (703) 312‐9580 or by emailing prospectuses@brileyfin.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the public offering and the anticipated use of the proceeds thereof. These forward-looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the proposed public offering and the risk factors set forth from time to time in Synchronoss’ SEC filings, including but not limited to the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections (as applicable) of Synchronoss’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the period ended March 31, 2021, which are on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Synchronoss’ other filings with the SEC, other unknown or unpredictable factors also could affect Synchronoss’ results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Synchronoss undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media

Diane Rose
CCgroup
diane@ccgrouppr.com

Investors

Todd Kehrli/Joo-Hun Kim
MKR Investor Relations, Inc.
investor@synchronoss.com